Dahlberg et al., 2025 - Google Patents
Multivalent Tri-Functional T-cell Engagers by Chemically Induced Protein Self-AssemblyDahlberg et al., 2025
View PDF- Document ID
- 15303866941110595297
- Author
- Dahlberg D
- McKnight B
- Kulkarni A
- Rozumalski L
- Rodriguez F
- Wang Y
- Wagner C
- Publication year
- Publication venue
- bioRxiv
External Links
Snippet
T-cell engagers (TCEs) show promise in cancer immunotherapy but face challenges in solid tumors due to heterogeneity, antigen escape, and limited T-cell infiltration. To address this, we developed a modular platform using chemically self-assembled nanorings (CSANs). We …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Katsarou et al. | Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence | |
| Cheng et al. | Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes | |
| AU2023203601B2 (en) | Ex vivo bite-activated T cells | |
| Hegde et al. | Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape | |
| JP2023085479A (en) | Synthetic immune receptors and methods of their use | |
| JP6821688B2 (en) | Chimeric antigen receptor and usage | |
| Urbanska et al. | A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor | |
| CN112840019B (en) | Chimeric antigen receptor polypeptides combined with trans-metabolism molecules regulating the Krebs cycle and their therapeutic uses | |
| JP2021512635A (en) | Chimeric antigen receptor targeting the tumor microenvironment | |
| EP3532490B1 (en) | Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens | |
| JP2024178177A (en) | Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy | |
| JP2020156488A (en) | Compositions and Methods for Treating Cancer with Anti-mesocerin Immunotherapy | |
| JP2020513829A (en) | Compositions and methods for treating cancer by anti-CD33 immunotherapy | |
| KR20200015717A (en) | Utilization of CD39 and CD103 for Identification of Human Tumor Reactive T Cells for Cancer Treatment | |
| JP2021510076A (en) | Immune cells expressing chimeric antigen receptor | |
| Chu et al. | Human antibodies targeting ENPP1 as candidate therapeutics for cancers | |
| Guo et al. | The SpyCatcher-SpyTag interaction mediates tunable anti-tumor cytotoxicity of NK cells | |
| Yu et al. | Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma | |
| Zhang et al. | Genetically reprogrammed exosomes for immunotherapy of acute myeloid leukemia | |
| AU2023390820A1 (en) | Chimeric antigen receptor | |
| Kuo et al. | Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells | |
| Domagala et al. | Ammonia inhibits antitumor activity of NK cells by decreasing mature perforin | |
| Dahlberg et al. | Multivalent Tri-Functional T-cell Engagers by Chemically Induced Protein Self-Assembly | |
| Wu et al. | Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma | |
| Potez et al. | Use of phage display biopanning as a tool to design CAR-T cells against glioma stem cells |